Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis by Balleari, E. et al.
Cancer Medicine. 2019;8:7567–7576.    | 7567wileyonlinelibrary.com/journal/cam4
Received: 7 May 2019 | Revised: 15 September 2019 | Accepted: 5 October 2019
DOI: 10.1002/cam4.2638  
O R I G I N A L  R E S E A R C H
Effects of different doses of erythropoietin in patients with 
myelodysplastic syndromes: A propensity score‐matched analysis
Enrico Balleari1,2  |   Rosa Angela Filiberti3 |   Chiara Salvetti1,4 |   Bernardino Allione1,5 |   
Emanuele Angelucci1,6 |   Marco Bruzzone3 |   Tullio Calzamiglia1,7 |   Marina Cavaliere1,8 |   
Maurizio Cavalleri1,9 |   Daniela Cilloni1,10 |   Marino Clavio1,11 |   Elena Crisà1,4 |    
Anna Da Col1,2 |   Paolo Danise1,12 |   Federica Pilo1,13 |   Dario Ferrero1,4 |   Carlo Finelli1,14 |   
Daniela Gioia1 |   Roberto Massimo Lemoli1,11 |   Elisa Masiera1 |   Emanuela Messa1,15 |   
Maurizio Miglino1,11 |   Pellegrino Musto1,16 |   Esther Natalie Oliva1,17 |   
Antonella Poloni1,18 |   Flavia Salvi1,19 |   Alessandro Sanna1,20 |   Marco Scudeletti1,9 |   
Rodolfo Tassara1,8 |   Valeria Santini1,21
1Fondazione Italiana Sindromi Mielodisplastiche (FISM), Bologna, Italy
2UO Internal Medicine, Ospedale Policlinico San Martino‐IRCCS, Genova, Italy
3UO Clinical Epidemiology, Ospedale Policlinico San Martino‐IRCCS, Genova, Italy
4UO Hematology, University of Turin, Torino, Italy
5UO Hematology, Molinette Hospital, Torino, Italy
6UO Hematology, Ospedale Policlinico San Martino‐IRCCS, Genova, Italy
7UO Internal Medicine—ASL 1, Sanremo (IM), Italy
8UO Internal Medicine—ASL 2, Savona, Italy
9UO Internal Medicine—ASL 4, Sestri Levante (GE), Italy
10UO Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
11UO Clinic of Hematology, Department of Internal Medicine, University of Genoa, Ospedale Policlinico San Martino‐IRCCS, Genova, Italy
12UO Hematology, Nocera Hospital, Nocera Inferiore, Italy
13UO Hematology—P.O. Oncologico Businco AOG. Brotzu, Cagliari, Italy
14UO Hematology, AOU Policlinico Sant’Orsola‐Malpighi, University of Bologna, Bologna, Italy
15UO Internal Medicine, ASLTo4, Carmagnola, Italy
16Regional Department of Hematology, IRCCS‐CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy
17UO Hematology, Grande Ospedale Metropolitano “Bianchi Melacrino Morelli”, Reggio Calabria, Italy
18UO Hematology, Università Politecnica delle Marche, Ancona, Italy
19UO Hematology, SS. Antonio e Biagio Hospital, Alessandria, Italy
20Ematologia, Ospedale di Livorno, Livorno, Italy
21MDS Unit, AOU Careggi, University of Florence, Firenze, Italy
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
7568 |   BALLEARI Et AL.
1 |  INTRODUCTION
Anemia is the major clinical concern for patients with my-
elodysplastic syndromes (MDS). It is present in about two 
of three patients at diagnosis, eventually rendering most of 
them transfusion dependent.1 Moreover, anemia is the main 
cause of both morbidity and mortality2 in MDS patients with 
a lower risk of progression according to the International 
Prognostic Scoring System (IPSS)3 and to its revised form 
(IPSS‐R).4
Erythropoietic‐stimulating agents (ESAs), in particular 
recombinant human erythropoietin (rhEPO), have been used 
to overcome anemia in MDS patients since the last three de-
cades, soon after it became available in clinics for the treat-
ment of anemia due to renal failure.5 ESAs have been shown 
to improve the clinical outcome of anemic MDS patients, 
ameliorating their quality of life,6,7 and possibly exerting a 
positive impact on survival in patients achieving a significant 
increase in hemoglobin (Hb) and/or a reduction of transfusion 
need.8,9 In 2018 rhEPO has been approved by EMA for IPSS 
lower‐risk MDS with endogenous levels <200 U/L and Hb 
<10 g/dL.
Unfortunately, not all patients treated with ESAs re-
spond. Early studies explored the effects of weight‐adjusted 
doses of rhEPO in MDS anemic patients. Using these doses, 
usually slightly inferior to 30‐40.000  IU weekly, an eryth-
roid response was obtained in 15%‐25% of MDS patients.10 
Although encouraging, these results were inferior to more 
recent ones reporting a response rate >50%.11,12 Higher re-
sponse rate to ESAs currently observed is due to the better 
selection of MDS patients based on criteria developed and 
consolidated over the years.9 The use of doses of rhEPO 
higher than 40.000  IU is also deemed responsible for the 
improvement of response rates,13-15 and it has been recently 
recommended.16 The real clinical impact of higher vs lower 
doses of ESAs has never been evaluated in a randomized 
study or in a pair‐matched comparison, and we hypothesized 
that this type of analysis would clarify the role of different 
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Abstract
Background: Erythropoiesis‐stimulating agents effectively improve the hemoglobin 
levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). 
Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been pro-
posed to overcome suboptimal response rates observed in MDS patients treated with 
lower “standard doses” (SD) of rhEPO. However, a direct comparison between the 
different doses of rhEPO is lacking.
Methods: A cohort of 104 MDS patients treated with HD was retrospectively com-
pared to 208 patients treated with SD in a propensity score‐matched analysis to evalu-
ate hematological improvement‐erythroid (HI‐E) rate induced by the different doses 
of rhEPO. The impact of rhEPO doses on survival and progression to leukemia was 
also investigated.
Results: Overall HI‐E rate was 52.6%. No difference was observed between different 
rhEPO doses (P = .28) in matched cohorts; in a subgroup analysis, transfusion‐depend-
ent patients and patients with higher IPSS‐R score obtained a higher HI‐E rate with 
HD, although without significant impact on overall survival (OS). Achievement of 
HI‐E resulted in superior OS. At univariate analysis, a higher HI‐E rate was observed 
in transfusion‐independent patients (P < .001), with a lower IPSS‐R score (P < .001) 
and lower serum EPO levels (P = .027). Multivariate analysis confirmed that rhEPO 
doses were not significantly related to HI‐E (P = .26). There was no significant differ-
ence in OS or progression to leukemia in patients treated with HD vs SD.
Conclusion: SD are substantially equally effective to HD to improve anemia and 
influencing survival in MDS patients stratified according to similar propensity to be 
exposed to rhEPO treatment.
K E Y W O R D S
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ESA doses in influencing response, overall survival, and pro-
gression to AML.
We thus retrospectively assessed the impact of higher vs 
lower doses of rhEPO on response to therapy and survival 
in two groups of MDS patients matched for clinical charac-
teristics determining propensity to receive ESAs treatment. 
We limited this evaluation to rhEPO, given the scarce use of 
darbepoetin for MDS patients in Italy.
2 |  PATIENTS AND METHODS
2.1 | Patient selection and data collection
This retrospective propensity‐matched cohort study was con-
ducted using the Italian nation‐wide dataset of Fondazione 
Italiana Sindromi Mielodisplastiche (FISM‐Onlus), which 
includes more than 5000 MDS patients enrolled in the Italian 
Network of regional MDS registries (ClinicalTrials.gov 
Identifier: NCT02808858). The study was approved by the 
Ethics Committee and conducted according to national regu-
lations for retrospective studies.
A cohort of MDS anemic patients treated with higher 
doses (HD) of rhEPO, defined as 40.000  IU twice a week, 
within 6 months from diagnosis was first identified. A second 
cohort, with a similar propensity to be treated with rhEPO ac-
cording to clinical parameters known to influence the choice 
for a trial with ESAs17,18 and treated with lower, “standard 
doses” (SD), defined as 40.000  IU weekly, was compared 
with the first one by using a 2:1 propensity score matching. 
Hematological improvement‐erythroid (HI‐E) was evaluated 
after 3 months of therapy, applying IWG 2006 criteria.19
2.2 | Statistical analysis
Demographics and clinical characteristic of the patients were 
summarized as median (range) for continuous variables and 
number (%) for categorical variables. Relationships between 
categorical variables were examined by means of chi‐square 
test. Univariate analyses were performed to evaluate the re-
sponse to therapy, progression to acute myeloid leukemia 
(AML), and prognostic impact on survival of individual and 
clinical variables. Overall survival (OS) was estimated using 
as survival time the difference (in months) between the date 
of death or last follow‐up and the date of start of therapy. 
Patients lost to follow‐up were censored at the date of their 
last visit. Kaplan‐Meier method was applied in univariate 
analysis to estimate survival probabilities and log‐rank test 
was carried out to assess heterogeneity within each prognos-
tic factor. The cumulative 1‐, 2‐, and 3‐year survival prob-
abilities were estimated.
To overcome mis‐estimating response to therapy and OS 
due to possible differences in patient baseline parameters 
between the two groups, a propensity score for each patient 
was calculated by a multivariable logistic regression analysis 
after allowance for age, MDS WHO 2008 classification, bone 
marrow blasts (<5% vs ≥5%), endogenous EPO (>200 vs 
≤200 mU/mL), transfusion dependency (yes vs no), Hb (>8 
vs ≤8 g/dL), ferritin (>350 vs ≤350 µg/L), and IPSS score 
(intermediate 1 or higher vs low). These variables were se-
lected as relevant and conditioning predictors of rhEPO dose 
choice. The logistic regression coefficients of the variables 
that were significant in the model were then used to compute 
the propensity score.20 This score represents the probability 
that a patient would receive treatment with higher rhEPO 
doses based on variables which were suspected to influence 
group assignment. A 1:2 matched study group was created 
with the use of the nearest approach.
To estimate the effect of treatment dose on HI‐E and pro-
gression to AML in matched‐pair analysis, a multivariate 
analysis was performed by the random intercept logistic re-
gression modeling for clustered data, adjusting for sex. The 
associated results are reported as odds ratio (OR) with 95% 
confidence intervals (CI). The effect of treatment doses and 
of sex on overall survival was estimated through the random 
intercept Cox regression modeling and the results are re-
ported as hazard ratios (HR) with 95% CI.
A two‐tailed P‐value <.05 was considered statistically 
significant. All analyses were performed using SPSS soft-
ware v. 20 by IBM.
3 |  RESULTS
3.1 | Characteristics of the study group of 
MDS patients
At the time of data lockup (31 December 2016), 445 ane-
mic patients (104 treated with HD and 341 with SD) with 
complete clinical annotations in the FISM registry satisfied 
the eligibility criteria and entered the study. Baseline patient 
characteristics, before matching, are reported in Table 1.
3.2 | Outcomes of the propensity score‐
matched cohorts
All the 104 MDS patients treated with HD were matched 
with 208 patients treated with SD in a 1:2 fashion. Detailed 
characteristics of these two cohorts at the time of starting 
treatment are shown in Table 2. After matching, all covari-
ates were well balanced, with nonsignificant difference in 
therapy‐related variables between the two cohorts.
3.3 | Achievement of HI‐E according to 
ESA doses
Overall, HI‐E was observed in 164 matched patients (52.6%). 
Nonsignificant differences were observed with regard to 
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rhEPO doses: HI‐E was obtained in 54.8% of patients with 
SD vs 48.1% with HD, respectively (P = .28).
At univariate analysis, a statistically significant higher 
HI‐E was observed in patients with transfusion indepen-
dence (no vs yes, P  <  .001), with an IPSS‐R lower‐risk 
score category (very low‐low vs intermediate‐very high, 
P < .001), and with lower serum EPO concentration (≤200 
vs >200, P =  .027). A trend to higher HI‐E was found in 
patients with <5% of marrow blasts (P =  .08). Fewer re-
sponses were observed in patients with del (5q) and RAEB2 
(20% and 25%, respectively) which were significantly dif-
ferent to response rates observed in RA (with or without 
ringed sideroblasts, RARS) and RCMD cases (58. 8% and 
47.6%, respectively, P = .04) (Table S1). Multivariate anal-
ysis taking into consideration rhEPO doses, transfusion 
dependency, serum EPO levels, marrow blast percentage, 
WHO classification, and IPSS‐R, confirmed the predictive 
value of transfusion dependency (no vs yes: OR  =  1.71, 
95% CI 1.30‐2.25; P < .001) and IPSS‐R (very low‐low vs 
higher risk: OR = 1.45, 95% CI 1.03‐2.06, P = .035) while 
patients with del (5q) were confirmed to have a lower re-
sponse rate (OR: 0.23, 95% CI 0.07‐0.79, P = .020). rhEPO 
doses were not significantly correlated with HI‐E (P = .39) 
(Table S2).
3.4 | Overall survival according to ESA 
doses and response
Median OS was 64.6  months (95% CI 49.2‐79.9  months). 
After a median observation time of 44.2  months (range 
1.6‐156.8) and 26.7 months (range 1.8‐114.6) for censored 
and deceased patients, respectively, 133 patients (42.6%: 
44.2% in SD and 39.4% in HD cohorts, respectively) died. 
One‐, 2‐ and 3‐year survival probabilities were 80%, 66%, 
and 37%, respectively. A no significant trend to longer OS 
was observed for the HD vs SD cohort (80.2 months, 95% CI 
T A B L E  1  Clinical characteristics of the patients at diagnosis. All 
patients (n = 445)
 
Therapy
P
Standard dose
N (%)
High dose
N (%)
Total 341 (76.6) 104 (23.4)  
Sex     <.001
Male 179 (52.5) 77 (74.0)  
Female 162 (47.5) 27 (26.0)  
Age median (range) 75 (39‐98) 75 (30‐96)  
≤75 176 (51.6) 57 (54.8) .58
>75 165 (48.4) 47 (45.2)  
WHO classification      
RA 132 (38.7) 30 (28.8)  
RARS 38 (11.1) 17 (16.5)  
RCMD 102 (29.9) 32 (31.1)  
RAEB1 33 (9.7) 15 (14.6)  
RAEB2 12 (3.5) 3 (2.9)  
MDS with isolated 
5q‐
20 (5.9) 4 (3.9)  
MDS‐U 4 (1.2) 2 (1.9)  
Not available — 1 (1.0)  
Hemoglobin median 
(range)g/dL
9.1 (2‐12.8) 8.9 (5.1‐13.1)  
≤8 74(21.7) 30(28.8) .15
>8 267(78.3) 74 (71.2)  
<9 203 (59.5) 64 (61.5) .73
>9 138 (40.5) 40 (38.5)  
<10 304 (89.1) 97 (93.3) .26
>10 37 (10.9) 7 (6.7)  
Bone marrow blasts (%)     .55
<5 287 (84.2) 85 (81.7)  
≥5 54 (15.8) 19 (18.3)  
Transfusion 
dependency
    .60
No 259 (76.0) 76 (73.1)  
Yes 82 (24.0) 28 (26.9)  
IPSS score risk     .013
Low 205 (60.1) 46 (44.2)  
Intermediate 1 112 (32.8) 52 (50.0)  
Intermediate 2 22 (6.5) 6 (5.8)  
High 2 (0.6) —  
IPSS‐R score risk     .26
Very low 74 (21.7) 22 (21.2)  
Low 162 (47.5) 39 (37.5)  
Intermediate 68 (19.9) 30 (28.8)  
(Continues)
 
Therapy
P
Standard dose
N (%)
High dose
N (%)
High 27 (7.9) 8 (7.7)  
Very high 10 (2.9) 5 (4.8)  
Ferritin median (range) 
μg/L
288 (4‐4985) 321.5 (6‐1600)  
≤350 200 (58.7) 47 (45.2) .018
>350 141 (41.3) 57 (54.8)  
EPO median (range) 
mU/mL
59.0 (2‐3420) 75 (1‐1700)  
≤200 289 (84.8) 80 (76.9) .074
>200 52 (15.2) 24 (23.1)  
T A B L E  1  (Continued)
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31.1‐129.3 for HD vs 58.5 months, 95% CI 42.3‐74.7 for SD; 
P = .78; Figure 1).
At univariate analysis, female gender (P = .010), younger age 
(≤75 year, P < .001), low ferritin levels (≤350, P = .010), trans-
fusion independence (P < .001), lower marrow blast percentage 
(≤5%, P  =  .001), and IPSS‐R lower‐risk category (low‐very 
low vs intermediate‐very high, P <  .001) were all significant 
positive prognostic factors for OS. Median OS was significantly 
shorter for RAEB and RCMD cases (31 and 40 months, respec-
tively) compared to RA and RARS cases (83 and 95 months, 
respectively, P = .002) (Table S3). Patients achieving HI‐E had 
a longer OS (median OS: 86.2 vs 52.3 m, P = .028; Figure 2A). 
Figure 2B shows the OS in the two cohorts of patients according 
to HI‐E achievement. Since median survival was not reached 
in some groups, mean values are reported. No significant dif-
ferences were observed according to rhEPO dose within the 
different subgroups (no responders: 75.1  months for SD and 
67.4 months for HD, P = .63; responders: 78.1 months for SD 
and 91.4 months for HD, P = .27).
A multivariate analysis carried out adjusting for gender, age, 
rhEPO dose, transfusion dependency, ferritin, marrow blasts, 
WHO classification, and IPSS‐R score, OS was confirmed to 
be better for younger patients (HR = 0.62, 95% CI 0.52‐0.75, 
P < .001) for those with lower IPSS‐R score (HR = 0.64, 95% 
CI 0.51‐0.82, P  <  .001) and with transfusion independence 
(HR = 0.78, 95% CI 0.65‐0.94, P = .010) (Table S4).
3.5 | Impact of clinical characteristics on 
response to HD or SD ESA doses
Within the HD and SD cohorts, we also investigated whether 
a higher HI‐E rate or a longer OS could be associated with 
T A B L E  2  Clinical characteristics of patients after propensity 
score matching (n = 312) at the start of rhEPO treatment
 
Propensity score‐matched patients
Therapy
P
Standard dose
N (%)
High dose
N (%)
Total 208 (66.7) 104 (33.3)  
Sex     <.001
Male 106 (51.0) 77 (74.0)  
Female 102 (49.0) 27 (26.0)  
Age median (range)     1.0
<75 114 (55.1) 57 (54.8)  
>75 93 (44.9) 47 (45.2)  
WHO classification     .90
RA 75 (36.1) 30 (28.8)  
RARS 26 (12.5) 17 (16.5)  
RCMD 60 (28.8) 32 (31.1)  
RAEB1 27 (13.0) 15 (14.6)  
RAEB2 5 (2.4) 3 (2.9)  
MDS with isolated 
5q‐
11 (5.3) 4 (3.9)  
MDS‐U 4 (1.9) 2 (1.9)  
Not available — 1 (1.0)  
Hemoglobin median 
(range) g/dL
     
≤8 47(22.6) 30(28.8) .26
>8 161(77.4) 74(71.2)  
<9 127 (61.1) 64 (61.5) 1.0
>9 81 (38.9) 40 (38.5)  
<10 188 (90.4) 97 (93.3) .52
>10 20 (9.6) 7 (6.7)  
Bone marrow blasts 
(%)
    1.0
<5 169 (81.3) 85 (81.7)  
>5 39 (18.8) 19 (18.3)  
Transfusion 
dependency
    .89
No 149(71.6) 76 (73.1)  
Yes 59 (28.4) 28 (26.9)  
IPSS score risk     .44
Low 104 (50.0) 46 (44.2)  
Intermediate 1 92 (44.2) 52 (50.0)  
Intermediate 2 10 (4.8) 6 (5.8)  
High 2 (1.0) —  
IPSS‐R score risk     .72
Very low 41 (19.7) 22 (21.2)  
(Continues)
 
Propensity score‐matched patients
Therapy
P
Standard dose
N (%)
High dose
N (%)
Low 91 (43.8) 39 (37.5)  
Intermediate 51 (24.5) 30 (28.8)  
High 19 (9.1) 8 (7.7)  
Very high 6 (2.9) 5 (4.8)  
Ferritin median 
(range) μg/L
    1.0
≤350 95 (45.7) 47 (45.2)  
>350 113 (54.3) 57 (54.8)  
EPO median (range) 
mU/mL
    .67
≤200 165 (79.3) 80 (76.9)  
>200 43 (20.7) 24 (23.1)  
T A B L E  2  (Continued)
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specific clinical characteristics. Figure 3A shows the sub-
group analyses regarding HI‐E and Figure 3B the analysis 
regarding OS. Higher HI‐E rate was observed in HD cohort 
compared with SD cohort in both transfusion‐dependent 
patients and higher IPSS‐R risk categories (P  =  .001 and 
P = .007 respectively), but no significant impact on OS was 
detected in these subgroups of prognostically more severe 
patients.
3.6 | Progression to AML according to 
ESA doses
Overall, 38 patients (12.2%) (14.4% in SD and 7.7% in HD 
group respectively), progressed to AML. Progression to AML 
was significantly higher among patients with transfusion de-
pendency (19.5% vs 9.3% in nondependent patients, P = .02), 
with higher marrow blast count (27.6% for ≥5% vs 8.6% for 
<5, P < .001), without HI‐E (18.9% vs 6.1% for responders, 
P  =  .001), and with higher IPSS‐R risk categories (27.0% 
for intermediate‐very high‐risk and 6.3% for low‐very low‐
risk scores, P = .001). Higher progression to AML, although 
not significant, was also observed among younger patients 
(15.1% ≤75 year vs 8.6% for >75 years, P = .085). A mul-
tivariate analysis adjusted for age, rhEPO dose, transfusion 
dependency, marrow blast percentage, WHO categories and 
IPSS‐R score, a higher blast percentage (>5%: OR = 1.91, 
95% CI 1.01‐3.60, P = .047) and IPSS‐R score (intermedi-
ate or higher: OR = 1.85, 95% CI 1.16‐2.95, P = .010) were 
predictive of progression to AML. rhEPO doses were not as-
sociated with AML progression (HD: OR  =  0.71, 95% CI 
0.46‐1.10, P = .13).
When restricting the analysis to the 274 patients who did 
not progress to AML, multivariate analysis confirmed that 
rhEPO doses were not associated with HI‐E (OR  =  0.90, 
95% CI 0.69‐1.17, P  =  .44). Transfusion dependence was 
associated with the lack of response (no vs yes: OR = 1.54, 
95% CI 1.15‐2.07, P = .004). Endogenous serum EPO lev-
els (≤200 U/L vs >200 U/L: OR = 1.33, 95% CI 0.96‐1.85, 
P  =  .083) were weakly associated with HI‐E as well as 
IPSS‐R risk categories (very low‐low vs intermediate or 
higher: OR = 1.41, 95% CI 0.95‐2.09, P = .083).
3.7 | Random intercept logistic regression 
analysis among propensity‐matched patients
The random intercept logistic regression modeling tak-
ing into account therapy and gender confirmed that rhEPO 
dose was not a predictive factor for response (HD vs SD: 
OR = 0.74, 95% CI 0.45‐1.22) (Table 3, model 1). No statis-
tically significant association was also seen between rhEPO 
doses and progression to AML (HD vs SD: OR = 0.48, 95% 
CI 0.20‐1.11) (Table 3, model 3). Higher‐dose rhEPO treat-
ment was not a positive prognostic factor for OS (HR = 0.82, 
95% CI 0.55‐1.21) (Table 4, model 1). Similar results were 
obtained when the analysis was restricted to patients not pro-
gressing to AML, with an OR of 0.66 (95% CI 0.40‐1.10) for 
HI‐E (Table 3, model 2) and a HR of 0.92 (95% CI 0.59‐1.46) 
for OS (Table 4, model 2).
4 |  DISCUSSION
Our study shows that anemic MDS patients treated with dif-
ferent rhEPO doses (either SD or HD) achieve similar HI‐E 
rates, provided that they have similar clinical characteristics 
influencing the eligibility for treatment with ESAs.
These results apparently contrast with previous studies 
on MDS anemic patients indicating a higher response rate 
to ESAs, and in particular to rhEPO, when HD are em-
ployed13,14 compared to SD.10 These latter poor results were 
mostly obtained in clinical studies performed in the early 90s 
using different but usually relatively low doses of rhEPO in 
the various subsets of MDS patients; in fact, in that early pe-
riod trials actually enrolled a relevant proportion of patients 
with more advanced MDS, including subjects with RAEB 
and/or patients with a greater transfusional need. Most of 
these patients would be in present days classified as “high‐
risk,” for whom to date treatment with ESAs is not generally 
considered an optimal choice.
Two meta‐analyses comparing studies performed in quite 
a long time lapse and with different dosing schedules in 
possibly heterogeneous groups of MDS patients indicated a 
possible superiority of HD of rhEPO vs SD. Data from 30 
selected studies on MDS patients treated with ESAs at dif-
ferent dosing showed that HD of both rhEPO and darbep-
oetin induced higher HI‐E in lower‐risk MDS.21 However, 
in a subsequent meta‐analysis focused on rhEPO, among 
MDS patients treated with SD a significantly higher number 
F I G U R E  1  Overall survival of propensity score‐matched 
patients according to rhEPO doses
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of cases had marrow blasts >5% than cases treated with HD 
and SD patients treated had significantly higher endogenous 
serum EPO levels.22 Both these factors are clearly related to a 
poor response to rhEPO9 and possibly influenced the clinical 
outcome. Strictly selected MDS lower‐risk patients treated 
with SD had response rates equivalent to those observed with 
HD.23,24 The recent randomized trial comparing safety and 
efficacy of rhEPO with placebo in low‐risk MDS patients 
used weight‐adjusted doses of rhEPO, substantially equiva-
lent to SD.25
Erythroid response to ESAs is determined in fact by 
several predictive factors, and different clinical scores 
have been proposed during the years. Beyond the Nordic 
score,17 when only “low‐risk” MDS anemic patients with 
a blast count of less than 10% and with a low transfusion 
burden were treated with rhEPO,26 response rate was actu-
ally more than doubled comparing with previous studies.10 
An IPSS‐R‐based predictive system has been more recently 
proposed considering also serum EPO and ferritin concen-
trations.18 It significantly predicted HI‐E after ESAs and 
F I G U R E  2  Overall survival of patients according to erythroid response in both cohorts (A) and within different subgroups according to 
different rhEPO doses (B)
F I G U R E  3  Forest plot of subgroup analyses of erythroid response (A) and overall survival (B) comparing rhEPO high dose (HD) vs rhEPO 
standard dose (SD) within the strata of each relevant clinical factor
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it was recently already validated by a larger study.27 In the 
present study, we compared two cohorts of patients accord-
ing to their eligibility to be treated with rhEPO applying a 
propensity score based on the clinical parameters influenc-
ing treatment choice. When the impact of different rhEPO 
doses was evaluated within such two homogenous cohorts 
the differences in response rates did not statistically differ. 
Transfusion‐dependent MDS patients and/or those with a 
higher IPSS‐R risk score in any case benefit more from HD 
than from SD, in terms of achievement of HI‐E. In these 
subsets of MDS patients, it would therefore be advisable to 
start treatment with HD ESAs, if other therapeutic options 
(ie, as example, hypomethylating agents) are not suitable 
or possible.
Our results are consistent with previous ones indicating 
longer OS in MDS patients who achieve HI‐E, at whichever 
rhEPO doses used.8,9 We recently demonstrated that a trend 
for survival advantage is present for MDS patients with iso-
lated erythroid dysplasia (RA/RARS/del5q) receiving ESAs 
for severe‐moderate anemia (8‐10 g/dL).28
Treatment with rhEPO—irrespectively of the doses 
used—do not have significant impact on progression to 
AML, which was higher among MDS patients not respond-
ing to rhEPO, transfusion‐dependent patients and with higher 
IPSS‐R risk scores, confirming previous results.29,30
In conclusion, although with the limits of a retrospec-
tive analysis and a relatively limited number of cases, our 
study indicates that the SD of rhEPO is as effective as HD 
in improving anemia in MDS patients stratified according 
to the propensity score of treatment, with the exception of 
transfusion‐dependent patients and with higher IPSS‐R 
risk scores. Moreover, different doses have the same ef-
fects on OS and risk of AML transformation. Our obser-
vations may lead to a wiser use of SD of rhEPO, reserving 
HD to the above indicated subcategories of MDS patients, 
limiting the economic impact of the treatment. It has been 
shown that early use of ESAs can significantly delay the 
onset of a transfusion need in lower‐risk MDS patients, and 
is associated with a reduced chance of death in responding 
patients.31 This further supports the relevance of our anal-
ysis in view of increased appropriateness in early therapy 
with ESAs.
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T A B L E  3  Effect of treatment doses and gender on erythroid response rates and progression to acute myeloid leukemia estimated through 
the random intercept logistic regression modeling, after matching patients on propensity score derived from age, endogenous EPO, transfusion 
dependency, Hb, ferritin, and IPSS score
Variable
Model 1 (n = 312) Model 2 (n = 274) Model 3 (n = 312)
OR 95% CL (P‐value) OR 95% CL (P‐value) OR
95% CL 
(P‐value)
Treatment: higher vs standard 
doses
0.74 0.45‐1.22 (.235) 0.66 0.40‐1.10 (.114) 0.48 0.20‐1.11 (.086)
Gender: female vs male 0.92 0.57‐1.50 (.737) 0.89 0.54‐1.47 (.646) 0.89 0.43‐1.84 (.753)
Note: Model 1: erythroid response as outcome, all patients; Model 2: erythroid response as outcome, leukemia‐free patients; Model 3: leukemia as outcome.
Abbreviations: 95% CL: 95% confidence limits for OR; OR: odds ratio; P‐value: significance level of the likelihood ratio test.
T A B L E  4  Effect of treatment doses and gender on overall survival estimated through the random intercept Cox regression modeling, after 
matching patients on propensity score derived from age, endogenous EPO, transfusion dependency, Hb, ferritin, and IPSS score
Variable
Model 1 (n = 312) Model 2 (n = 274)
HR 95% CL (P‐value) HR 95% CL (P‐value)
Treatment: higher vs standard doses 0.82 0.55‐1.21 (.318) 0.92 0.59‐1.46 (.747)
Gender: female vs male 0.51 0.34‐0.78 (.002) 0.50 0.31‐0.82 (.006)
Note: Model 1: all patients; Model 2: leukemia‐free patients.
Abbreviations: 95% CL, 95% confidence limits for HR; HR, hazard ratio; P‐value, significance level of the likelihood ratio test.
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